Policy
In a Cabinet meeting, Health Secretary Robert F. Kennedy Jr. said the website could go live “probably in the next 10 days,” but an exact launch date remains unclear.
FEATURED STORIES
An inconsistent boom-and-bust cycle funding environment for early-stage biotech innovations and burdensome regulation threaten the U.S.’s half-century-long dominance in the biotech sector.
Acadia Pharma’s Catherine Owen Adams is one of the founders of a group of small- to mid-cap biotechs advocating against a ‘peanut butter blanket’ approach to drug pricing for small companies.
Former European Trade Commissioner Phil Hogan and former U.S. Senator Richard Burr, speaking on a panel at the J.P. Morgan Healthcare Conference, pushed to see a larger picture beyond the Trump administration’s year of chaos and confusion.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
The federal watchdog said it was responding to a letter it received from Director Dr. Mark Smith at Kelyniam in June.
Mark Lanier, a lead attorney for the plaintiffs in one of six cases being tried raised the tampering issue during an Oct. 16 hearing.
The lawsuit was filed on behalf of members of the American military who were injured or killed by attacks between 2005 and 2009
Buried in its third-quarter financial announcement, J&J indicated it was dropping two of its pipeline drugs with little or no explanation.
A San Diego bankruptcy court issued a final judgement that two former Masimo employees had misappropriated trade secrets, which they turned over to Sotera Wireless.
Incyte has levelled charges of stealing company secrets against the founders of Flexus Biosciences over the hiring of Incyte’s former CSO who had access to Incyte’s scientific research.
What’s the best way to address high drug prices? That’s a tough question, but one angle that gets less public attention is the high cost of early-stage development.
The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee unanimously recommended Spark’s Luxturna in a vote of 16 to 0.